Voltage-dependent N-type Ca2+ channels in endothelial cells contribute to oxidative stress-related endothelial dysfunction induced by angiotensin II in mice.

[1]  P. Vanhoutte,et al.  State of the Art Lecture , 2018, European Psychiatry.

[2]  M. Nishida,et al.  Redox control of cardiovascular homeostasis by angiotensin II. , 2013, Current pharmaceutical design.

[3]  K. Nitta,et al.  Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats , 2013, Clinical and Experimental Nephrology.

[4]  S. Takai,et al.  Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats , 2012, Hypertension Research.

[5]  T. Murohara,et al.  Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats , 2012, Journal of hypertension.

[6]  T. Wakatsuki,et al.  Renoprotective and antioxidant effects of cilnidipine in hypertensive patients , 2012, Hypertension Research.

[7]  M. Nishida,et al.  Cilostazol Suppresses Angiotensin II–Induced Vasoconstriction via Protein Kinase A–Mediated Phosphorylation of the Transient Receptor Potential Canonical 6 Channel , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[8]  M. Nishida,et al.  TRPC3-mediated Ca2+ influx contributes to Rac1-mediated production of reactive oxygen species in MLP-deficient mouse hearts. , 2011, Biochemical and biophysical research communications.

[9]  M. Nishida,et al.  Heterologous down-regulation of angiotensin type 1 receptors by purinergic P2Y2 receptor stimulation through S-nitrosylation of NF-κB , 2011, Proceedings of the National Academy of Sciences.

[10]  H. Toba,et al.  L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin–angiotensin–aldosterone system in deoxycorticosterone acetate-salt hypertensive rats , 2011, Hypertension Research.

[11]  T. Fujita,et al.  Comparison of antioxidant activity of cilnidipine and amlodipine. , 2009, Kidney international.

[12]  A. Takahara.  Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. , 2009, Cardiovascular therapeutics.

[13]  M. Nishida,et al.  P2Y6 receptor‐Gα12/13 signalling in cardiomyocytes triggers pressure overload‐induced cardiac fibrosis , 2008, The EMBO journal.

[14]  G. Yasuda,et al.  Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. , 2007, Kidney international.

[15]  T. Iwasaka,et al.  Renal and vascular protective effects of cilnidipine in patients with essential hypertension , 2007, Journal of hypertension.

[16]  T. Rabelink,et al.  Endothelial function and dysfunction: testing and clinical relevance. , 2007, Circulation.

[17]  K. Homma,et al.  Ca2+ channel subtypes and pharmacology in the kidney. , 2007, Circulation research.

[18]  P. Hjemdahl,et al.  Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity , 2007, Journal of hypertension.

[19]  Z. Ungvari,et al.  Mechanosensitive production of reactive oxygen species in endothelial and smooth muscle cells: role in microvascular remodeling? , 2006, Antioxidants & redox signaling.

[20]  S. Mathur,et al.  Angiotensin II–Induced Vascular Dysfunction Is Mediated by the AT1A Receptor in Mice , 2004, Hypertension.

[21]  L. Ghiadoni,et al.  Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies. , 2003, Current pharmaceutical design.

[22]  T. Takami,et al.  Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[23]  Steven M. Holland,et al.  Mechanical Stretch Enhances mRNA Expression and Proenzyme Release of Matrix Metalloproteinase‐2 (MMP‐2) via NAD(P)H Oxidase‐Derived Reactive Oxygen Species , 2003, Circulation research.

[24]  M. Nishida,et al.  Ca(2+) channel alpha(1B) subunit (Ca(V) 2.2) knockout mouse reveals a predominant role of N-type channels in the sympathetic regulation of the circulatory system. , 2002, Trends in cardiovascular medicine.

[25]  Sheryl E. Koch,et al.  Functional disorders of the sympathetic nervous system in mice lacking the α1B subunit (Cav 2.2) of N-type calcium channels , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Gail Mandel,et al.  Nomenclature of Voltage-Gated Sodium Channels , 2000, Neuron.

[27]  R. Tsien,et al.  Nomenclature of Voltage-Gated Calcium Channels , 2000, Neuron.

[28]  U. Ravens,et al.  Voltage-sensitive Ca2+ channels, intracellular Ca2+ stores and Ca2+-release-activated Ca2+ channels contribute to the ATP-induced [Ca2+]i increase in differentiated neuroblastoma×glioma NG 108-15 cells , 1999, Neuroscience Letters.

[29]  N. Akaike,et al.  Blockade of N‐type Ca2+ current by cilnidipine (FRC‐8653) in acutely dissociated rat sympathetic neurones , 1997, British journal of pharmacology.

[30]  M. Hosono,et al.  Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons. , 1997, The Journal of pharmacology and experimental therapeutics.

[31]  F. Leenen,et al.  Clinical relevance of 24 h blood pressure control by 1,4-dihydropyridines. , 1996, American journal of hypertension.

[32]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[33]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[34]  W. Weglicki,et al.  Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. , 1990, Circulation research.

[35]  W R Gray,et al.  Peptide neurotoxins from fish-hunting cone snails. , 1985, Science.

[36]  T. Lohmeier,et al.  Chronic angiotensin II infusion decreases renal norepinephrine overflow in conscious dogs. , 1984, Hypertension.

[37]  Gian Paolo Rossi,et al.  Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. , 2005, Journal of hypertension.

[38]  R. Tsien,et al.  Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. , 1988, Science.